All In MedTech

FDA Clearance Tracker · P160045-S025

Oncomine Dx Target Test

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 29, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 29, 2023

Approved

Time to decision

1,019 days

Received Dec 14, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160045-S025
Device name
Oncomine Dx Target Test
Applicant location
Carlsbad, CA
Received
Dec 14, 2020
Decided
Sep 29, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160045

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of the BRAF V600E positive anaplastic thyroid cancer patients (ANA) for dabrafenib and tramatenib (Mekinist/Tafinlar).

Source documents

Other decisions for Life Technologies Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.